Welcome to LookChem.com Sign In|Join Free
The company logo of Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Free supplier Enterprise Certification

Free
supplier
8th
years

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Business Type:Lab/Research institutions

Audited Supplier

Main Products:
Year Established:
2017
Home>>Products>>ETP-46321

Products Categories

Product Certification&
Enterprise Certification

More Detail

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Country: China (Mainland)

Business Type:Lab/Research institutions

ETP-46321

CAS NO.1252594-99-2

  • Min.Order: 10 Milligram
  • Payment Terms:
Contact Supplier

Product Details

Keywords

  • ETP-46321
  • ETP46321
  • best price and high purity

Quick Details

  • ProName: ETP-46321
  • CasNo: 1252594-99-2
  • Molecular Formula: C20H27N9O3S
  • Application: For laboratory use only- not intended ...
  • ProductionCapacity: 1 Kilogram/Month
  • Purity: ≥98%
  • Storage: room temperature
  • Transportation: by air
  • LimitNum: 10 Milligram

Superiority

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

 

 

 

Details

ETP-46321 is a potent and orally bioavailable PI3K α/δ inhibitor with IC50 of 2.3/14.2 nM for p110α/p110β; exhibits potency on mutated p110α(IC50=1.77-2.33 nM, p110a E542K; E545K; H1047R). IC50 value: 2.3/14.2 nM(p110α/p110β) Target: PI3K α/δ inhibitor ETP-46321, has been pro led and shown to be a potent PI3K a and d inhibitor, highly selective versus mTOR and 288 representative kinases. The compound demonstrated a good pharmacokinetic profile in mice and was selected for preliminary in vivo evaluation in a lung tumor mouse model driven by a K-Ras G12V oncogenic mutation, showing significant tumor growth inhibition (ca. 51%), and reduction of the tumor metabolic activity as measured by PET techniques.

Hot Product